ZAMP Bionews

Targanta Therapeutics Corporation (Nasdaq: TARG) today announced that oritavancin, the Company’s investigational antibiotic therapy for the treatment of complicated skin and skin structure infections (cSSSI) caused by gram-positive pathogens, including methicillin resistant Staphylococcus aureus (MRSA), received a mixed review from the United States Food and Drug Administration’s (FDA) Anti-Infective Drugs Advisory Committee.

[...]

The Quality and Outcomes Framework (QOF) is one government target that has brought real benefit to patients across the UK, the BMA said today (Wednesday 19 November 2008). Responding to a report from Civitas, which claims the QOF offers inappropriate financial incentives, Dr Laurence Buckman, Chairman of the BMA’s GP Committee, said:

[...]

The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8; London AIM: PAI) today announces that it has successfully completed a Phase I study with its intravenous sedative/anaesthetic CNS 7056. The study was completed ahead of schedule because the target criterion, more than 50% of the volunteers reaching loss of consciousness for [...]

To bring awareness about a devastating disease that affects thousands of Kentuckians and their families, Gov. Steve Beshear has proclaimed November Alzheimer’s Disease Awareness Month in Kentucky.
Alzheimer’s disease (AD) is the most common form of the brain diseases known as dementia. AD is a progressive, degenerative brain disease that often starts with slight memory loss [...]

“While there was a suggestion that DFMO may influence the extent of Barrett’s dysplasia, this finding is very preliminary and further study of this agent in a larger number of patients is needed,” said Frank A. Sinicrope, M.D., professor of medicine and oncology at the Mayo Clinic, Rochester, MN.

Tags: abnormal cells, [...]